Trial Profile
A Phase 1b Open Label Clinical Trial to Evaluate HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs HIV gp120 vaccine (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 02 Oct 2020 Status changed from active, no longer recruiting to completed.
- 18 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Jan 2019 Status changed from not yet recruiting to recruiting.